Exclusion Criteria:~* Evidence of neurodegenerative disease other than AD~* Inability for any reason to undergo
MRI scans (e.g. pacemaker, vascular stent or stent graft). Patients who require sedation for screening
procedures such as MRI may receive a short-acting sedative.~* Psychiatric disorder that would compromise
ability to comply with study requirements~* History of cancer within the last 5 years, except basal cell
carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression
over the past 2 years~* Significant cardiovascular, pulmonary, renal, liver, infectious disease, immune
disorder or metabolic/endocrine disorders or other disease that would preclude treatment with p38 MAP kinase
inhibitor and/or assessment of drug safety and efficacy~* Recent (<90 days) changes to AD medications
prescribed for cognitive reasons or with the potential to impact cognition~* Psychotropic drugs taken within 1
month. Anticoagulant drugs taken within 1 week.~* Participation in a study of an investigational drug less than
6 months or 5 half-lives of the investigational drug, whichever is longer, before enrollment in the study~*
Male subjects with female partner of child-bearing potential who are unwilling or unable to adhere to
contraception requirements~* Female subjects who have not reached menopause or have not had a hysterectomy or
bilateral oophorectomy/salpingoophorectomy~* Positive urine or serum pregnancy test or plans desires to become
pregnant during the course of the trial~* Donation of >500 mL of blood or blood products within 2 months~*
History of alcohol and/or illicit drug abuse within 6 months.~* Infection with hepatitis A, B or C or HIV.~*
Any factor deemed by the investigator to be likely to interfere with study conduction
